Spyre Therapeutics Initiated at Outperform by Wedbush
Spyre Therapeutics Analyst Ratings
Wedbush Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $45
Analysts' Top Healthcare Picks: PMV Pharmaceuticals (PMVP), Spyre Therapeutics (SYRE)
TD Cowen Remains a Buy on Spyre Therapeutics (SYRE)
Spyre Therapeutics Analyst Ratings
Spyre Therapeutics Analyst Ratings
Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook
Spyre Therapeutics Analyst Ratings
Spyre Therapeutics Analyst Ratings
Buy Rating Affirmed for Spyre Therapeutics on Promising MAb Dosing and Market Positioning
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating
Spyre Therapeutics Analyst Ratings
Strong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial Position
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)
Spyre Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)
Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)
Buy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel Optimism
TD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
No Data